Clinical Trial

Niraparib/TTFields in GBM

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Evaluating the efficacy and safety of niraparib and Tumor-Treating Fields (TTFields) in recurrent glioblastoma (GBM).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2020-01-07; most recent amendment 2026-01-06.
Status change: Recruiting → Active, Not Recruiting 2023-01-30
Status change: Active, Not Recruiting → Recruiting 2020-07-01
Status change: Recruiting → Active, Not Recruiting 2020-03-23
Trial Details
NCT Number NCT04221503
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: Tesaro, Inc., NovoCure Ltd.
Conditions Glioblastoma, Recurrent Glioblastoma, GBM
Enrollment 30 participants
Start Date 2019-12-30
Primary Completion 2026-01 (estimated)
Study Completion 2026-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-08